# Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia

> **NCT01556763** · PHASE1 · COMPLETED · sponsor: **FORUM Pharmaceuticals Inc** · enrollment: 21 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Central Nervous System Diseases

## Interventions

- **DRUG:** EVP-6124 (0.3 mg/day)
- **DRUG:** EVP-6124 (1.0 mg/day)
- **DRUG:** Placebo
- **DRUG:** Antipsychotic therapy

## Key facts

- **NCT ID:** NCT01556763
- **Lead sponsor:** FORUM Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-04
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2012-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01556763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01556763, "Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01556763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*